# EDGAR Filing Document

**Accession Number:** 0001401040
**File Stem:** 0001437749-23-006195
**Filing Date:** 2023-3
**Character Count:** 4570
**Document Hash:** 4793578bdc6201d4460abfb439c2c058
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-006195.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001437749-23-006195

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DiaMedica Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001401040
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36291
- **FILM NUMBER:** 23724313

**BUSINESS ADDRESS:**
- **STREET 1:** 301 CARLSON PARKWAY
- **STREET 2:** SUITE 210
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55305
- **BUSINESS PHONE:** (763) 496-5454

**MAIL ADDRESS:**
- **STREET 1:** 301 CARLSON PARKWAY
- **STREET 2:** SUITE 210
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55305

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DiaMedica Inc.
- **DATE OF NAME CHANGE:** 20070525

dmtp20230310_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM **8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

------

Date of Report (Date of earliest event reported): **March 10, 2023**

------

**DIAMEDICA THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-36291** | **Not Applicable** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |
| **301 Carlson Parkway, Suite 210**<br> **Minneapolis, **Minnesota** | **55305** | **55305** |
| (Address of principal executive offices) | (Zip Code) | (Zip Code) |

---

**(**763**) **496-5454**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Voting common shares, no par value per share | DMAC | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

**Item 7.01. Regulation FD Disclosure.**

On March 10, 2023, DiaMedica Therapeutics Inc. announced that it does not hold cash deposits or securities at Silicon Valley Bank.

The information contained in Item 7.01 of this report shall not be deemed to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference into any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **DIAMEDICA THERAPEUTICS INC.** | **DIAMEDICA THERAPEUTICS INC.** |
| By:  | /s/ Scott Kellen |
|  | Scott Kellen |
|  | Chief Financial Officer and Secretary |

---

Dated: March 10, 2023